Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy
Launched by MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER · Jun 23, 2017
Trial Information
Current as of May 27, 2025
Unknown status
Keywords
ClinConnect Summary
This study is a double-blinded randomized control trial comparing tilmanocept to TSC as intraoperative radiolabeled mapping agents in female patients with early stage breast cancer undergoing partial mastectomy with SLNBx.
To secure this aim, patients who are schedule to undergo partial mastectomy and SLBx will be consented and randomized (randomization table) into one of two experimental arms, tilmanocept or TSC.
These patients will then undergo their scheduled partial mastectomy with SLNBx, with the patient and surgeon blinded to the randomization result.
The respective radiotracers wi...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women above 18 years of age with biopsy proven, clinically stage 1 or 2 breast cancer who will be undergoing partial mastectomy with SLNBx at Memorial Health
- Exclusion Criteria:
- • Women under the age of 18,
- • Clinically positive axillary nodes
- • Neoadjuvant therapy for current breast cancer diagnosis
- • Women with previous SLNBx or axillary node dissection
- • Pregnant women
- • Women with previous radiation above the diaphragm, and below the neck
About Memorial Health University Medical Center
Memorial Health University Medical Center (MHUMC) is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. Located in Savannah, Georgia, MHUMC is committed to delivering high-quality, evidence-based treatment options while fostering a collaborative environment for researchers, healthcare professionals, and participants. With a focus on a diverse range of therapeutic areas, the center aims to enhance healthcare outcomes and contribute to the body of medical knowledge through rigorous scientific inquiry and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Savannah, Georgia, United States
Patients applied
Trial Officials
William Burak, MD
Principal Investigator
Memorial Health University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials